uniQure (NASDAQ:QURE – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and price targets for uniQure and ProKidney, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| uniQure | 1 | 3 | 12 | 1 | 2.76 |
| ProKidney | 1 | 0 | 1 | 1 | 2.67 |
uniQure presently has a consensus price target of $53.25, indicating a potential upside of 134.38%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 733.33%. Given ProKidney’s higher possible upside, analysts plainly believe ProKidney is more favorable than uniQure.
Volatility & Risk
uniQure has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
Profitability
This table compares uniQure and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| uniQure | -1,350.73% | -111.96% | -29.01% |
| ProKidney | -10,288.39% | N/A | -27.39% |
Earnings & Valuation
This table compares uniQure and ProKidney”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| uniQure | $16.10 million | 97.89 | -$198.97 million | ($4.01) | -5.67 |
| ProKidney | $890,000.00 | 489.15 | -$68.99 million | ($0.55) | -2.62 |
ProKidney has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
78.8% of uniQure shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
ProKidney beats uniQure on 8 of the 13 factors compared between the two stocks.
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
